Novel drug targets for asthma and COPD: Lessons learned from in vitro and in vivo models

K.E. Baker, S.J. Bonvini, C. Donovan, Rachel Foong, B. Han, A. Jha, Y. Shaifta, M. Smit, J.R. Johnson, L.M. Moir

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Asthma and chronic obstructive pulmonary disease (COPD) are highly prevalent respiratory diseases characterized by airway inflammation, airway obstruction and airway hyperresponsiveness. Whilst current therapies, such as β-agonists and glucocorticoids, may be effective at reducing symptoms, they do not reduce disease progression. Thus, there is a need to identify new therapeutic targets. In this review, we summarize the potential of novel targets or tools, including anti-inflammatories, phosphodiesterase inhibitors, kinase inhibitors, transient receptor potential channels, vitamin D and protease inhibitors, for the treatment of asthma and COPD.
Original languageEnglish
Pages (from-to)181-198
JournalPulmonary Pharmacology and Therapeutics
Volume29
Issue number2
Early online date11 Jun 2014
DOIs
Publication statusPublished - Dec 2014

    Fingerprint

Cite this

Baker, K. E., Bonvini, S. J., Donovan, C., Foong, R., Han, B., Jha, A., ... Moir, L. M. (2014). Novel drug targets for asthma and COPD: Lessons learned from in vitro and in vivo models. Pulmonary Pharmacology and Therapeutics, 29(2), 181-198. https://doi.org/10.1016/j.pupt.2014.05.008